The Association of Diagnostics Manufacturers of India (ADMI) warmly welcomes the Government of India’s decision to reduce Goods and Services Tax (GST) to 5% for IVD analyzers (HSN 9027) and diagnostic kits and reagents (HSN 3822). ADMI extends its sincere gratitude to Hon’ble Prime Minister Shri Narendra Modi, Hon’ble Union Finance Minister Smt. Nirmala Sitharaman, Hon’ble Minister of Commerce & Industry Shri Piyush Goyal, and the Secretary, Department of Pharmaceuticals (DoP), as well as the GST Council, for this landmark, patient-centric reform.This decisive step will lower the cost of essential diagnostic tests, expand access across tier-2 and tier-3 cities, and strengthen India’s Make in India vision by improving competitiveness of Indian manufacturers and MSMEs. Hospitals, labs, and patients will benefit from a simpler, lower rate structure that supports preventive and primary healthcare. “The GST Council’s decision is a major win for patients and for India’s diagnostics ecosystem,” said Mr. Jatin Mahajan, President, ADMI. “It will catalyse affordable testing, spur innovation and investment, and accelerate domestic manufacturing in the IVD sector.” Dr. Rajesh M. Patel, Secretary, ADMI, added: “We extend our heartfelt thanks to the Hon’ble Prime Minister and Hon’ble Finance Minister for their leadership. ADMI members will ensure benefits are passed on transparently and will support a smooth transition with industry guidance and compliance.” Mr. Sanjeev Lala, Vice President, ADMI, said: “Harmonising GST at 5% for analyzers and reagent kits removes a long-standing anomaly and brings predictability to the value chain. This step will lower test costs, strengthen Make in India, and spur MSME-led innovation.” Mr. Chirag Joshi, Treasurer, ADMI, said: “Industry will transparently pass this relief to hospitals, labs, and patients. ADMI will issue clear guidance on HSN 9027/